Business Wire: Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the ... Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications Business Wire: Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases Oxitope Pharma and Arxx Therapeutics have announced their merger to form Calluna Pharma, which has raised €75m in a series A financing, to develop novel therapies for immunological diseases. The new ...
Yahoo Finance: Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director OSLO, Norway & BOSTON, --(BUSINESS WIRE)--Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, ...
